Jaclyn Cordero

455 total citations
10 papers, 343 citations indexed

About

Jaclyn Cordero is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Jaclyn Cordero has authored 10 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 5 papers in Hematology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Jaclyn Cordero's work include Chronic Lymphocytic Leukemia Research (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Lymphoma Diagnosis and Treatment (3 papers). Jaclyn Cordero is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Lymphoma Diagnosis and Treatment (3 papers). Jaclyn Cordero collaborates with scholars based in United States, France and Australia. Jaclyn Cordero's co-authors include Sari H. Enschede, Jeremy A. Ross, Maria Verdugo, Ahmed Hamed Salem, Shaji Kumar, Wijith Munasinghe, Paulo Maciag, Joel Johansson, Asher Chanan‐Khan and Cyrille Touzeau and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Jaclyn Cordero

9 papers receiving 341 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jaclyn Cordero United States 6 209 204 143 133 81 10 343
Hannah Hunter United Kingdom 8 312 1.5× 202 1.0× 160 1.1× 85 0.6× 63 0.8× 21 397
Fernando Escalante Spain 10 236 1.1× 171 0.8× 120 0.8× 84 0.6× 41 0.5× 36 325
Efstathios Koulieris Greece 10 141 0.7× 88 0.4× 103 0.7× 106 0.8× 85 1.0× 24 262
Firoz Ahmad India 11 142 0.7× 118 0.6× 61 0.4× 80 0.6× 34 0.4× 38 296
J. Maciejewski United States 7 259 1.2× 180 0.9× 30 0.2× 107 0.8× 30 0.4× 10 345
Yaozhong Zhao China 10 219 1.0× 152 0.7× 146 1.0× 57 0.4× 27 0.3× 20 314
Dushyant Verma United States 10 415 2.0× 102 0.5× 51 0.4× 289 2.2× 48 0.6× 14 486
Xenofon Papanikolaou United States 7 241 1.2× 167 0.8× 150 1.0× 50 0.4× 20 0.2× 30 310
Anne Banos France 10 167 0.8× 127 0.6× 73 0.5× 81 0.6× 57 0.7× 27 261
Guillaume Richard‐Carpentier United States 12 239 1.1× 118 0.6× 101 0.7× 68 0.5× 53 0.7× 27 370

Countries citing papers authored by Jaclyn Cordero

Since Specialization
Citations

This map shows the geographic impact of Jaclyn Cordero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaclyn Cordero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaclyn Cordero more than expected).

Fields of papers citing papers by Jaclyn Cordero

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaclyn Cordero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaclyn Cordero. The network helps show where Jaclyn Cordero may publish in the future.

Co-authorship network of co-authors of Jaclyn Cordero

This figure shows the co-authorship network connecting the top 25 collaborators of Jaclyn Cordero. A scholar is included among the top collaborators of Jaclyn Cordero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaclyn Cordero. Jaclyn Cordero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Vos, Sven de, L. J. Swinnen, Dee Dee Wang, et al.. (2018). Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Annals of Oncology. 29(9). 1932–1938. 51 indexed citations
2.
Costa, Luciano J., Edward A. Stadtmauer, Gareth J. Morgan, et al.. (2018). Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 36(15_suppl). 8004–8004. 17 indexed citations
3.
Swinnen, L. J., Christopher R. Flowers, Dee Dee Wang, et al.. (2017). VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY. Hematological Oncology. 35(S2). 90–90. 4 indexed citations
4.
Moreau, Philippe, Asher Chanan‐Khan, Andrew W. Roberts, et al.. (2017). A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 17(1). e16–e16.
5.
Moreau, Philippe, Asher Chanan‐Khan, Andrew W. Roberts, et al.. (2017). Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 130(22). 2392–2400. 205 indexed citations
6.
Moreau, Philippe, Asher Chanan‐Khan, Andrew W. Roberts, et al.. (2016). Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. Blood. 128(22). 975–975. 18 indexed citations
7.
Moreau, Philippe, Asher Chanan‐Khan, Andrew W. Roberts, et al.. (2016). Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 34(15_suppl). 8011–8011. 3 indexed citations
8.
9.
10.
Luis, Daniel Antonio de, Jaclyn Cordero, D Boixeda, et al.. (2001). Effect of the treatment of Helicobacter pylori infection on gastric emptying and its influence on the glycaemic control in type 1 diabetes mellitus. Diabetes Research and Clinical Practice. 52(1). 1–9. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hannah Hunter Breakdown of academic impact, for papers by Fernando Escalante Breakdown of academic impact, for papers by Efstathios Koulieris Breakdown of academic impact, for papers by Firoz Ahmad Breakdown of academic impact, for papers by J. Maciejewski Breakdown of academic impact, for papers by Yaozhong Zhao Breakdown of academic impact, for papers by Dushyant Verma Breakdown of academic impact, for papers by Xenofon Papanikolaou Breakdown of academic impact, for papers by Anne Banos Breakdown of academic impact, for papers by Guillaume Richard‐Carpentier
Rankless by CCL
2026